These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 35814395)

  • 1. Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation.
    Qu J; Shen Q; Li Y; Kalyani FS; Liu L; Zhou J; Zhou J
    Front Oncol; 2022; 12():911303. PubMed ID: 35814395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Dabrafenib Plus Trametinib Combination in Patients with
    Auliac JB; Bayle S; Do P; Le Garff G; Roa M; Falchero L; Huchot E; Quéré G; Jeannin G; Métivier AC; Hobeika J; Guisier F; Chouaid C
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33276639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer.
    Mu Y; Yang K; Hao X; Wang Y; Wang L; Liu Y; Lin L; Li J; Xing P
    Front Oncol; 2020; 10():603. PubMed ID: 32411601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
    Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
    Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful re-challenge of dabrafenib-trametinib combination therapy in advanced
    Xue Y; Ren Y; Yan B; Li Z; Huang C
    Ann Transl Med; 2022 Sep; 10(18):1029. PubMed ID: 36267742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.
    Meng P; Koopman B; Kok K; Ter Elst A; Schuuring E; van Kempen LC; Timens W; Hiltermann TJN; Groen HJM; van den Berg A; van der Wekken AJ
    Lung Cancer; 2020 Aug; 146():358-361. PubMed ID: 32534795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dabrafenib and trametinib administration in patients with
    Shimoi T; Sunami K; Tahara M; Nishiwaki S; Tanaka S; Baba E; Kanai M; Kinoshita I; Shirota H; Hayashi H; Nishida N; Kubo T; Mamesaya N; Ando Y; Okita N; Shibata T; Nakamura K; Yamamoto N
    EClinicalMedicine; 2024 Mar; 69():102447. PubMed ID: 38333370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of non-small cell lung cancer patients with non-V600E
    Lazar R; Fischbach C; Schott R; Somme L
    Front Oncol; 2024; 14():1307882. PubMed ID: 38601760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dabrafenib plus trametinib in patients with previously untreated BRAF
    Planchard D; Smit EF; Groen HJM; Mazieres J; Besse B; Helland Å; Giannone V; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
    Lancet Oncol; 2017 Oct; 18(10):1307-1316. PubMed ID: 28919011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring
    Perrone F; Mazzaschi G; Minari R; Verzè M; Azzoni C; Bottarelli L; Nizzoli R; Pluchino M; Altimari A; Gruppioni E; Sperandi F; Andrini E; Guaitoli G; Bertolini F; Barbieri F; Bettelli S; Longo L; Pagano M; Bonelli C; Tagliavini E; Nicoli D; Ubiali A; Zangrandi A; Trubini S; Proietto M; Gnetti L; Tiseo M
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case report: Dual dabrafenib and trametinib therapy for treating BRAF V600E mutated lung adenocarcinoma with BRCA2 germline mutation post multiline progression.
    Zhang H; Cong X; Yin J; Chen C; Liu Z
    Front Oncol; 2024; 14():1387388. PubMed ID: 38715777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse Event Management in Patients with
    Chalmers A; Cannon L; Akerley W
    Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting BRAF mutations in non-small cell lung cancer.
    O'Leary CG; Andelkovic V; Ladwa R; Pavlakis N; Zhou C; Hirsch F; Richard D; O'Byrne K
    Transl Lung Cancer Res; 2019 Dec; 8(6):1119-1124. PubMed ID: 32010589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.
    Cardarella S; Ogino A; Nishino M; Butaney M; Shen J; Lydon C; Yeap BY; Sholl LM; Johnson BE; Jänne PA
    Clin Cancer Res; 2013 Aug; 19(16):4532-40. PubMed ID: 23833300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with non-small-cell lung cancer harbouring a
    Auliac JB; Bayle S; Vergnenegre A; Le Caer H; Falchero L; Gervais R; Doubre H; Vinas F; Marin B; Chouaid C
    Curr Oncol; 2018 Oct; 25(5):e398-e402. PubMed ID: 30464690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.
    Li J; Wang Q; Ge J; Tian Y; Yao W
    Oncologist; 2021 Dec; 26(12):e2115-e2119. PubMed ID: 34516041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis.
    Chen J; Lu W; Chen M; Cai Z; Zhan P; Liu X; Zhu S; Ye M; Lv T; Lv J; Song Y; Wang D
    Ther Adv Med Oncol; 2024; 16():17588359231225036. PubMed ID: 38420602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia).
    Sakai T; Matsumoto S; Ueda Y; Shibata Y; Ikeda T; Nakamura A; Kodani M; Ohashi K; Furuya N; Izumi H; Nosaki K; Umemura S; Zenke Y; Udagawa H; Sugiyama E; Yoh K; Goto K
    J Thorac Oncol; 2023 Nov; 18(11):1538-1549. PubMed ID: 37543207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dabrafenib plus trametinib in patients with BRAF
    Subbiah V; Lassen U; Élez E; Italiano A; Curigliano G; Javle M; de Braud F; Prager GW; Greil R; Stein A; Fasolo A; Schellens JHM; Wen PY; Viele K; Boran AD; Gasal E; Burgess P; Ilankumaran P; Wainberg ZA
    Lancet Oncol; 2020 Sep; 21(9):1234-1243. PubMed ID: 32818466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer.
    Myall NJ; Henry S; Wood D; Neal JW; Han SS; Padda SK; Wakelee HA
    Clin Lung Cancer; 2019 Mar; 20(2):e208-e217. PubMed ID: 30442523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.